Press Release
Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression
Australia, 27th Jan 2026 – Neuralia TMS, a respected provider of non-invasive neuromodulation therapies, has announced an expansion of access to Transcranial Magnetic Stimulation treatment for individuals living with depression, reflecting continued developments in evidence-based mental health care and increasing demand for non-pharmacological treatment options. The expanded availability is intended to support patients seeking additional clinical pathways under medical supervision.
Transcranial Magnetic Stimulation, commonly known as TMS, is a non-invasive procedure that uses targeted magnetic pulses to stimulate specific areas of the brain associated with mood regulation. The treatment does not involve medication or surgery and is delivered in an outpatient setting. Over the past two decades, TMS has been studied extensively and incorporated into treatment guidelines in several countries for individuals with major depressive disorder, particularly where symptoms have persisted despite standard treatment approaches.
The expanded access initiative follows increased clinical interest in treatment pathways that complement existing mental health care models. Depression remains a significant public health concern, with many individuals experiencing ongoing symptoms that affect daily functioning, work participation, and quality of life. In response, mental health services continue to explore a broader range of evidence-based interventions that can be delivered safely and effectively under medical supervision.
Dr Shanek Wick, Medical Director at Neuralia TMS, said the expansion reflects a focus on improving availability of established neuromodulation therapies for appropriate patients. “Transcranial Magnetic Stimulation is a non-invasive treatment option that has been supported by a growing body of clinical research for the management of depression,” Dr Wick said. “Broadening access allows more individuals to be assessed for suitability within a structured medical framework.”
Neuralia TMS provides TMS therapy as part of a comprehensive clinical assessment process, ensuring that treatment plans are informed by individual health history and current clinical needs. Sessions are typically delivered over a course of scheduled appointments, allowing patients to continue with usual daily activities during treatment. Reported side effects are generally mild and temporary, most commonly including scalp discomfort or headache during early sessions.
In addition to depression-focused care, Neuralia TMS offers neuromodulation services for a range of neurological and psychiatric conditions, including anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, chronic pain, and Parkinson’s disease. The clinic also provides transcranial Direct Current Stimulation, an at-home neuromodulation therapy delivered under clinical guidance, and pharmacogenetic testing to support personalised treatment planning based on genetic factors. These services are integrated into broader care considerations rather than positioned as replacements for established mental health treatments.
The expansion of TMS access aligns with wider trends in mental health care that emphasise individualised treatment planning and multidisciplinary approaches. Clinicians increasingly recognise that effective management of depression often involves combining multiple evidence-based strategies, including psychological therapies, medication, and non-invasive interventions. Neuromodulation therapies are being considered as part of this broader continuum of care.
Health sector observers note that non-invasive brain stimulation continues to attract attention as research into brain function and mental health advances. Ongoing clinical studies are exploring how treatment protocols may be refined and how outcomes can be better predicted across different patient groups. Within this context, careful clinical oversight and adherence to established standards remain central to responsible implementation.
Dr Wick said continued evaluation and clinical development will remain important as the field evolves. “Future directions in neuromodulation are expected to involve more precise targeting, improved individualisation of treatment protocols, and closer integration with other mental health services,” Dr Wick said. “Ongoing research and clinical review will play an important role in guiding how these therapies are applied over time.”
Neuralia TMS stated that all patients undergo a comprehensive medical assessment to determine whether TMS is clinically appropriate. The clinic operates in accordance with established medical and professional standards, with an emphasis on informed decision-making and patient safety.
The announcement comes amid continued public discussion about access to timely and evidence-based mental health care. By expanding access to non-invasive TMS treatment for depression, Neuralia TMS aims to contribute to the availability of additional clinical options for individuals and referring practitioners seeking alternatives within a medically supervised setting.
For further information regarding the expanded access to TMS treatment for depression, media enquiries may be directed to Neuralia TMS. The clinic can be contacted by phone on 08 6230 3996 or via email at info@neuralia.com.au.
Media Contact
Organization: Neuralia TMS
Contact Person: Dr Shanek Wick
Website: https://www.neuraliatms.com.au/
Email: Send Email
Contact Number: +61862303996
Country:Australia
Release id:40609
Disclaimer: This announcement is provided for general informational purposes only and does not constitute medical advice. Transcranial Magnetic Stimulation suitability and outcomes vary by individual and should be determined through assessment by a qualified medical professional.
The post Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
New York City, NY, USA, July 22nd, 2026, FinanceWire
Knot, the leading merchant connectivity platform, has announced its partnership with RBC, Canada’s largest bank, to make RBC cards the default payment method for millions of cardholders wherever they spend. Using Knot’s CardSwitcher, RBC cardholders can set their RBC card as the saved payment method at their favorite merchants directly from the RBC mobile app, without manually entering card details. The partnership marks Knot’s first expansion beyond the United States.
Keeping RBC Top of Wallet
One of the hardest moments in payments is the first one. When a cardholder gets a new RBC card, putting it to use means hunting down every merchant where a card is already saved and updating each one by hand, so a new card often sits idle for weeks before it sees real spend. The partnership removes that friction. From the RBC app, cardholders add their RBC card to their preferred merchants in a few taps and set it as the saved payment method at the places they already spend, from the day the card is in hand.
For RBC, that means a card that goes to work immediately instead of waiting to be activated across a cardholder’s everyday spend. Placing the card as the default at the merchants cardholders use most keeps it top of wallet, turning a new RBC card from an occasional choice into a go-to payment method from the start and driving repeat spend and deeper loyalty to RBC.
Expanding into Canada with the Country’s Largest Bank
For years, Knot has built the merchant connectivity layer across the United States, linking the people, financial institutions, and merchants behind everyday spend. RBC is where that infrastructure goes international for the first time. Canada is Knot’s first market beyond the U.S., and launching it with the country’s largest bank sets the standard for every market that follows.
RBC did not become Canada’s largest bank by standing still. They move early, they invest in their clients, and they push the industry forward. That is exactly the kind of partner Knot wants to build alongside, and the reason RBC is the right first step into a new market. Bringing CardSwitcher to Canadian cardholders is the start of a longer roadmap, both for what Knot and RBC build together and for where Knot goes next.
About RBC
Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Its success comes from the 101,000+ employees who leverage their imaginations and insights to bring the company’s vision, values, and strategy to life so it can help its clients thrive and communities prosper. As Canada’s biggest bank, and one of the largest in the world based on market capitalization, RBC has a diversified business model with a focus on innovation and providing exceptional experiences to its more than 19 million clients in Canada, the U.S., and 27 other countries. Learn more at rbc.com.
About Knot
Knot is the leading merchant connectivity platform, simplifying how consumers, merchants, and financial institutions interact. CardSwitcher is the foundation of Knot’s product suite, letting users update and manage card-on-file payments across hundreds of merchants. Building on the same connectivity infrastructure, TransactionLink delivers SKU-level transaction data, and SubManager gives users a single place to view and manage their subscriptions. By removing friction at every step, Knot helps financial institutions grow engagement, loyalty, and spend.
Users can learn more at KnotAPI.com and connect with Knot on X (@KnotAPIs) and LinkedIn (LinkedIn.com/company/KnotAPI).
Contact
Head of Growth
Jose Del Real
Knot
press@knotapi.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
New York City, USA, July 22nd, 2026, FinanceWire
RedotPay, a global stablecoin-based payment fintech, today announced it has been named to CNBC’s World’s Top Fintech Companies 2026 list, in the Payments category. RedotPay’s inclusion in the prestigious list reflects the growth of the company, which is the global leader in stablecoin consumer payments by volume and has over eight million users.
The list is compiled independently by CNBC and Statista, based on the past year’s performance data. Now in its fourth edition, the list honors 500 companies across nine market segments — Payments, Wealth Technology, Neobanking, Alternative Financing, Digital Assets, Enterprise Fintech, Insurtech, Regtech, and Others. For each segment, performance indicators and other metrics were used to evaluate and select companies for inclusion on the list.
“We’re honored to be recognized as a leading payments fintech company by CNBC and Statista. Stablecoin-powered payments are quickly becoming trusted by millions around the world, especially among those who don’t have reliable access to traditional banking infrastructure. We remain focused on making everyday stablecoin payments accessible to many more around the world,” said Michael Gao, CEO and Co-Founder of RedotPay.
The recognition reflects RedotPay’s continued focus on making stablecoin payments accessible, reliable, and compliant for customers and businesses globally. The company recently surpassed $1bn in monthly total payment volume. Its investors include Goodwater, Galaxy, Pantera, and Lightspeed.
About RedotPay
RedotPay is a global stablecoin-based payment fintech that integrates blockchain solutions with traditional banking and finance infrastructure. Our intuitive platform empowers millions around the world to spend and send digital assets, ensuring faster, more accessible and inclusive financial services. RedotPay advances financial inclusion for the unbanked and supports crypto enthusiasts, driving global adoption of secure and flexible stablecoin-powered financial solutions to bring crypto to real life. For more information, visit www.redotpay.com.
Contact
RedotPay
press@redotpay.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
ISO-Accredited Lab Testing Exposes 86% Failure Rate in Amazon Creatine Gummies, with Over Half Containing Near-Zero Active Ingredients
Dyad Labs Certificates of Analysis (#1406738-1 through #1462360-1) confirm widespread misbranding and dosage fraud across 15 popular e-commerce listings.
SALT LAKE CITY, Utah / LOS ANGELES, Calif. — A comprehensive market investigation evaluating 15 top-selling creatine gummy products on Amazon has uncovered systemic label fraud and active-ingredient under-dosing in the sports nutrition sector.
Analytical testing performed by Dyad Labs (A Mérieux NutriSciences Company, accredited under ISO/IEC 17025:2017) reveals that 13 out of 15 tested brands (86.7%) failed to meet their labeled claims of 5,000 mg of Creatine Monohydrate per serving.
The quantitative analysis was conducted using Method GL-604 (Determination of Creatine Monohydrate by Ultra-Performance Liquid Chromatography – UPLC), the recognized testing standard for active supplement compounds.
Shocking Laboratory Findings Across 15 Tested ASINs
According to official Certificates of Analysis (COA), 60% of tested products (9 out of 15) contained less than 1,000 mg per serving, with several extreme cases delivering less than 0.5% of the active ingredient promised on their labels:
· Near-Zero Active Creatine (<25 mg/serving):
·
Asumtal ASIN:B0F5VRJHPT/COACert#1450795-1: Tested <23.6 mg/serving (Label claim: 5,000 mg).
WELLNESS LABSRX ASIN:B0DCC4R4Q5/COACert#1450796-1: Tested <23.9 mg/serving (Label claim: 5,000 mg).
eterlower ASIN:B0FWXGC15Y/COACert#1450798-1: Tested <24.0 mg/serving (Label claim: 5,000 mg).
TASTY GAINS Collagen ASIN:B0FYPWMPZ9/COACert#1450797-1: Tested <24.0 mg/serving (Label claim: 5,000 mg).
· Severe Mislabeling & Under-Dosing (<654 mg/serving):
·
ZyterX ASIN:B0FF1R5T1Q/COACert#1406740-1: Tested <420 mg/serving.
TASTY GAINS ASIN:B0FH5J5GS4/COACert#1406739-1: Tested <454 mg/serving.
OUTELANDE ASIN:B0F4QJP5L3/COACert#1462359-1: Tested <500 mg/serving.
INNER BRIGHTNESS ASIN:B0FNBN38V4/COACert#1462360-1: Tested <500 mg/serving.
Cytona ASIN:B0F8BKD1CQ/COACert#1406747-1: Tested <654 mg/serving.
· Substantial Shortfalls (26% to 52% Deficit):
·
TASTY GAINS ASIN:B0D7N3D5X9/COACert#1406741-1: Tested 2,390 mg/serving (52% under-dosed).
Natures Aid ASIN:B0F3JBGGGZ/COACert#1406738-1: Tested 3,330 mg/serving (33% under-dosed).
Arrae ASIN:B0DX1RRWSY/COACert#1450801-1: Tested 3,410 mg/serving (32% under-dosed).
OMNI Creatine ASIN:B0F7J6DQ1V/COACert#1460718-1: Tested 3,710 mg/serving (26% under-dosed).
· Near-Compliant Top Performers:
·
Nutravita ASIN:B0CXMV6FBG/COACert#1406746-1: Tested 4,570 mg/serving.
DANEW Pro ASIN:B0DJ5HXHZS/COACert#1460717-1: Tested 4,780 mg/serving.
Master Table: Dyad Labs Analytical Certificates (ISO 17025)
| Brand Name | ASIN | Certificate ID | Testing Method | Labeled Claim | UPLC Result | Compliance Status |
|---|---|---|---|---|---|---|
| Asumtal | B0F5VRJHPT | #1450795-1 | GL-604 (UPLC) | 5,000 mg | <23.6 mg | Severe Fraud (<0.5%) |
| WELLNESS LABSRX | B0DCC4R4Q5 | #1450796-1 | GL-604 (UPLC) | 5,000 mg | <23.9 mg | Severe Fraud (<0.5%) |
| TASTY GAINS | B0FYPWMPZ9 | #1450797-1 | GL-604 (UPLC) | 5,000 mg | <24.0 mg | Severe Fraud (<0.5%) |
| eterlower | B0FWXGC15Y | #1450798-1 | GL-604 (UPLC) | 5,000 mg | <24.0 mg | Severe Fraud (<0.5%) |
| ZyterX | B0FF1R5T1Q | #1406740-1 | GL-604 (UPLC) | 9,000 mg (Tot) | <420 mg | Severely Misbranded |
| TASTY GAINS | B0FH5J5GS4 | #1406739-1 | GL-604 (UPLC) | 5,000 mg | <454 mg | Severely Misbranded |
| OUTELANDE | B0F4QJP5L3 | #1462359-1 | GL-604 (UPLC) | 5,000 mg | <500 mg | Severely Misbranded |
| INNER BRIGHTNESS | B0FNBN38V4 | #1462360-1 | GL-604 (UPLC) | 5,000 mg | <500 mg | Severely Misbranded |
| Cytona | B0F8BKD1CQ | #1406747-1 | GL-604 (UPLC) | 5,000 mg | <654 mg | Severely Misbranded |
| TASTY GAINS | B0D7N3D5X9 | #1406741-1 | GL-604 (UPLC) | 5,000 mg | 2,390 mg | Substantial Deficit (-52%) |
| Natures Aid | B0F3JBGGGZ | #1406738-1 | GL-604 (UPLC) | 5,000 mg | 3,330 mg | Deficit (-33%) |
| Arrae | B0DX1RRWSY | #1450801-1 | GL-604 (UPLC) | 5,000 mg | 3,410 mg | Deficit (-32%) |
| OMNI Creatine | B0F7J6DQ1V | #1460718-1 | GL-604 (UPLC) | 5,000 mg | 3,710 mg | Deficit (-26%) |
| Nutravita | B0CXMV6FBG | #1406746-1 | GL-604 (UPLC) | 5,000 mg | 4,570 mg | Near-Compliant |
| DANEW Pro | B0DJ5HXHZS | #1460717-1 | GL-604 (UPLC) | 5,000 mg | 4,780 mg | Near-Compliant |
Formulation Bottlenecks in Gummy Manufacturing
Food science specialists explain that Creatine Monohydrate degrades rapidly into inactive creatinine when exposed to high processing temperatures, water activity, and acidic environments—conditions intrinsic to gummy candy manufacturing. Without advanced stabilization microencapsulation, the active compound either breaks down during production or is deliberately under-dosed by manufacturers to prevent texture degradation.
Regulatory Filings and Enforcement Escalation
The complete documentation package, referencing all 15 Dyad Labs Certificates of Analysis (#1406738-1 through #1462360-1), has been submitted to:
The U.S. Food and Drug Administration (FDA) MedWatch Safety Portal
The Federal Trade Commission (FTC) Bureau of Consumer Protection
State Attorneys General Offices for investigation into deceptive marketing practices
Consumer advocacy groups are demanding that e-commerce marketplaces enforce mandatory, third-party batch verification for all gummy-form supplement listings.
Note to Editors / Media Verification:
Complete, unedited Certificates of Analysis (COA Certificate IDs #1406738-1 through #1462360-1) issued by ISO/IEC 17025 accredited Dyad Labs are officially on file and available to accredited media representatives upon request
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Knot Expands into Canada, Partnering with RBC, the Country’s Largest Bank
RedotPay Recognized as One of the World’s Top Fintech Companies by CNBC
ISO-Accredited Lab Testing Exposes 86% Failure Rate in Amazon Creatine Gummies, with Over Half Containing Near-Zero Active Ingredients
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release2 days ago
Samruk-Kazyna and Huawei Discuss AI Infrastructure Development in Kazakhstan
-
Press Release2 days ago
Kazakhstan and China to Establish a Smart Transportation Corridor
-
Press Release4 days ago
How ProfitPilot AI Is Transforming Intelligent Investing The Vision of Global Capital Partners Investments LLC
-
Press Release4 days ago
Brian Baldari, Brick NJ ResilExec Coach, Explains Why Adaptability Is the Leadership Skill That Separates Leaders Who Advance From Leaders Who Plateau
-
Press Release4 days ago
8 Cylinders Auto Repair Philadelphia Expands Professional Auto Repair and Maintenance Services
-
Press Release4 days ago
Where GCC’s Most Consequential Business Decisions Get Made
-
Press Release4 days ago
Joe Shields Brings Software Design Thinking to Hospitality Through States of Leisure’s Experience-First Approach
-
Press Release4 days ago
Terrance Bradford Tampa, FL Explains Why Problem-Solving Is One of Construction’s Most Valuable Skills